{"id":"NCT00690820","sponsor":"Solvay Pharmaceuticals","briefTitle":"Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)","officialTitle":"A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 12,000 Unit Capsules in Subjects Aged 7 - 11 With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2008-06-05","resultsPosted":"2010-03-10","lastUpdate":"2010-06-02"},"enrollment":17,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis","Pancreatic Exocrine Insufficiency"],"interventions":[{"type":"DRUG","name":"Pancrelipase Delayed Release","otherNames":[]},{"type":"DRUG","name":"Placebo Comparator","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the effect of pancrelipase delayed release 12,000 unit capsules on fat and nitrogen absorption in subjects 7 - 11 with pancreatic exocrine insufficiency due to Cystic Fibrosis.","primaryOutcome":{"measure":"Coefficient of Fat Absorption (%)","timeFrame":"5 days","effectByArm":[{"arm":"Placebo","deltaMin":47.41,"sd":16.84},{"arm":"Pancrelipase","deltaMin":82.81,"sd":8.29}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":["20171415","21681115"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Abdominal Pain","Diarrhoea","Flatulence","Vomiting","Blood glucose increased"]}}